Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Front Neurol
2023 Jan 01;14:1212079. doi: 10.3389/fneur.2023.1212079.
Show Gene links
Show Anatomy links
KCNC2 variants of uncertain significance are also associated to various forms of epilepsy.
Seiffert S
,
Pendziwiat M
,
Hedrich UBS
,
Helbig I
,
Weber Y
,
Schwarz N
.
???displayArticle.abstract???
Recently, de novo variants in KCNC2, coding for the potassium channel subunit KV3.2, have been described as causative for various forms of epilepsy including genetic generalized epilepsy (GGE) and developmental and epileptic encephalopathy (DEE). Here, we report the functional characteristics of three additional KCNC2 variants of uncertain significance and one variant classified as pathogenic. Electrophysiological studies were performed in Xenopus laevis oocytes. The data presented here support that KCNC2 variants with uncertain significance may also be causative for various forms of epilepsy, as they show changes in the current amplitude and activation and deactivation kinetics of the channel, depending on the variant. In addition, we investigated the effect of valproic acid on KV3.2, as several patients carrying pathogenic variants in the KCNC2 gene achieved significant seizure reduction or seizure freedom with this drug. However, in our electrophysiological investigations, no change on the behavior of KV3.2 channels could be observed, suggesting that the therapeutic effect of VPA may be explained by other mechanisms.
Figure 1. Electrophysiological analysis of the KCNC2 variants F382C, I465V, N530H and S333T. (A) Mean current amplitudes of oocytes injected with WT (n = 47), S333T (n = 17) and equal amounts of WT + S333T (n = 13). (B) Mean voltage-dependent activation of KV3.2 channels for WT (n = 47), S333T (n = 17) and equal amounts of WT + S333T (n = 13). Lines illustrate Boltzmann Function fit to the data points. (C) Mean voltage-dependent deactivation time constant of KV3.2 channel WT (n = 46), S333T (n = 17) and WT + S333T (n = 13). (D) Mean current amplitudes of oocytes injected with WT (n = 47), F382C (n = 27) and equal amounts of WT + F382C (n = 23). (E) Mean voltage-dependent activation of KV3.2 channel for WT (n = 47) and equal amounts of WT + F382C (n = 23). Lines illustrate Boltzmann Function fit to the data points. (F) Mean voltage-dependent deactivation time constant of KV3.2 channel WT (n = 46) and WT + F382C (n = 20). (G) Mean current amplitudes of oocytes injected with WT (n = 47), I465V (n = 17) and equal amounts of WT + I465V (n = 15). (H) Mean voltage-dependent activation of KV3.2 channel for WT (n = 47) and equal amounts of WT + I465V (n = 15). Lines illustrate Boltzmann Function fit to the data points. (I) Mean voltage-dependent deactivation time constant of KV3.2 channel WT (n = 46) and WT + I465V (n = 15). (J) Mean current amplitudes of oocytes injected with WT (n = 47), N530H (n = 12) and equal amounts of WT + N530H (n = 18). (K) Mean voltage-dependent activation of KV3.2 channel for WT (n = 47), N530H (n = 12) and equal amounts of WT + N530H (n = 18). Lines illustrate Boltzmann Function fit to the data points. (L) Mean voltage-dependent deactivation time constant of KV3.2 channel WT (n = 46), N530H (n = 12) and WT + N530H (n = 17). All data are shown as means ± SEM. Statistically significant differences are indicated by an asterisk (*p < 0.05).
Figure 2. Application of 30 mM VPA does not affect KV3.2 WT channels. (A) Mean current amplitudes of oocytes injected with WT and recorded as baseline (n = 42), after perfusion with bath solution containing 0 mM VPA (n = 17) and after perfusion with bath solution containing 30 mM VPA (n = 12). (B) Mean voltage-dependent activation of KV3.2 channels for WT (n = 47), after 0 mM VPA (n = 17) and after 30 mM VPA (n = 12). Lines illustrate Boltzmann Function fit to the data points. (C) Mean voltage-dependent deactivation time constants of KV3.2 channels for WT (n = 47), after 0 mM VPA (n = 17) and after 30 mM VPA (n = 12). All data are shown as means ± SEM.
Biervert,
A potassium channel mutation in neonatal human epilepsy.
1998, Pubmed,
Xenbase
Biervert,
A potassium channel mutation in neonatal human epilepsy.
1998,
Pubmed
,
Xenbase
Gu,
Kv3 channel assembly, trafficking and activity are regulated by zinc through different binding sites.
2013,
Pubmed
Hauser,
Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota.
1996,
Pubmed
Johannessen,
Mechanisms of action of valproate: a commentatory.
2000,
Pubmed
Jumper,
Highly accurate protein structure prediction with AlphaFold.
2021,
Pubmed
Kaczmarek,
International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium-Activated and Sodium-Activated Potassium Channels.
2017,
Pubmed
Kaczmarek,
Kv3 Channels: Enablers of Rapid Firing, Neurotransmitter Release, and Neuronal Endurance.
2017,
Pubmed
Kay,
M-current preservation contributes to anticonvulsant effects of valproic acid.
2015,
Pubmed
Lerche,
Ion channels in genetic and acquired forms of epilepsy.
2013,
Pubmed
Löscher,
Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.
2002,
Pubmed
Masnada,
Clinical spectrum and genotype-phenotype associations of KCNA2-related encephalopathies.
2017,
Pubmed
,
Xenbase
Møller,
Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies.
2016,
Pubmed
Richards,
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
2015,
Pubmed
Rudy,
Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing.
2001,
Pubmed
Schwarz,
Spectrum of Phenotypic, Genetic, and Functional Characteristics in Patients With Epilepsy With KCNC2 Pathogenic Variants.
2022,
Pubmed
,
Xenbase
Sewing,
Kv beta 1 subunit binding specific for shaker-related potassium channel alpha subunits.
1996,
Pubmed
Singh,
A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns.
1998,
Pubmed
Syrbe,
De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy.
2015,
Pubmed
VanDongen,
Valproate reduces excitability by blockage of sodium and potassium conductance.
1986,
Pubmed
,
Xenbase
Varadi,
AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models.
2022,
Pubmed
Walden,
Effects of valproate on early and late potassium currents of single neurons.
1993,
Pubmed
Zanatta,
Valproic acid interactions with the NavMs voltage-gated sodium channel.
2019,
Pubmed